Accolade

Accolade PEG

Delisted

The PEG Ratio (Price/Earnings-to-Growth) of Accolade (ACCD) as of Oct 11, 2026 is -0.07.

PEG

-0.07

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Accolade is 2024 -0.07 . PEG Ratio (Price/Earnings-to-Growth) of Accolade was 2023 - . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Accolade Stock analysis

What does Accolade do? Accolade Inc is a US-American company based in Seattle. The company was founded in 2007 by Rajeev Singh and Mike Hilton and has since developed into a leading healthcare consulting firm. Accolade aims to make healthcare simple and affordable for everyone. The company offers a wide range of solutions to its customers. It provides services to employers, insurance companies, and health authorities. Their main focus is on supporting patients and employees in their healthcare. They also offer services to health insurance companies and health authorities. The business model of Accolade involves close collaboration between the customers and the company. Patients are supported by a "Health Assistant," who are trained professionals that help patients make the best decisions regarding their health. Factors such as finding the best providers, medication delivery, clinical tests, and alternative options are considered. Accolade's mission is to improve healthcare for everyone by providing the best solutions. The company has divided itself into several different divisions to offer its services more effectively. The various divisions of Accolade include healthcare consulting, medication management, patient access and health navigation, client support, and health optimization. Accolade has become an important healthcare service provider and has earned a good reputation in the industry. The company is known for providing comprehensive and high-quality services that focus on individual patient care. When it comes to achieving improvements in care and the entire healthcare system, Accolade is an important partner that helps companies and individuals achieve their goals and lead healthier lives. Accolade is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accolade stock

PEG Ratio (Price/Earnings-to-Growth) of Accolade is -0.07 in 2024.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Accolade since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Accolade with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Accolade

All Key Metrics — Accolade